Eupraxia Pharmaceuticals (NASDAQ:EPRX) Issues Quarterly Earnings Results

Eupraxia Pharmaceuticals (NASDAQ:EPRX) posted its earnings results on Thursday. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.21), Zacks reports.

Eupraxia Pharmaceuticals Stock Down 1.4%

EPRX traded down $0.11 during trading hours on Thursday, hitting $7.41. The stock had a trading volume of 147,437 shares, compared to its average volume of 230,267. Eupraxia Pharmaceuticals has a 1 year low of $2.68 and a 1 year high of $9.32. The company’s fifty day simple moving average is $8.30 and its 200 day simple moving average is $6.87. The stock has a market cap of $266.28 million, a PE ratio of -7.20 and a beta of 1.27.

Key Headlines Impacting Eupraxia Pharmaceuticals

Here are the key news stories impacting Eupraxia Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright retains a “Buy” rating and a $11 price target on EPRX, signaling continued analyst conviction in the company’s longer‑term upside despite lowered near‑term estimates. HC Wainwright Coverage
• Positive Sentiment: Lifesci Capital keeps a “Strong‑Buy” stance on EPRX, indicating another buy‑side vote of confidence even as it trimmed FY2026 EPS. Lifesci Capital Coverage
• Neutral Sentiment: HC Wainwright published detailed quarterly and multi‑year EPS projections (Q1‑Q4 2026 and FY2026–FY2030), offering a clearer—if weaker—earnings roadmap for modelers; their long‑run FY2030 estimate is a positive +$0.17. HC Wainwright Estimates
• Negative Sentiment: Zacks Research downgraded EPRX from “Hold” to “Strong Sell,” a near‑term negative that likely pressured sentiment and trading. Zacks Downgrade
• Negative Sentiment: HC Wainwright materially cut EPS forecasts across FY2026–FY2029 (examples: FY2026 to ($0.96) from ($0.52); FY2028 to ($1.05) from ($0.63); FY2029 to ($0.42) from ($0.13)), signaling a weaker multi‑year outlook and increasing near‑term execution/financial risk. This is a substantive negative for valuation and sentiment. HC Wainwright Forecast Cuts
• Negative Sentiment: Lifesci Capital lowered its FY2026 EPS forecast (to ($0.88) from ($0.75)), weakening near‑term consensus even though the firm keeps a Strong‑Buy rating. Lifesci Estimate Change

Analyst Ratings Changes

A number of brokerages recently commented on EPRX. Zacks Research downgraded Eupraxia Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Thursday, January 22nd. HC Wainwright reduced their price objective on Eupraxia Pharmaceuticals from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday. Lifesci Capital raised Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, December 11th. Finally, Cantor Fitzgerald lifted their target price on Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the stock an “overweight” rating in a research note on Thursday, January 15th. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $15.00.

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vivo Capital LLC purchased a new position in shares of Eupraxia Pharmaceuticals in the third quarter worth about $7,965,000. Ikarian Capital LLC purchased a new stake in shares of Eupraxia Pharmaceuticals during the 4th quarter valued at approximately $4,606,000. Squadron Capital Management LLC bought a new position in Eupraxia Pharmaceuticals in the 4th quarter worth approximately $3,775,000. Velan Capital Investment Management LP bought a new position in Eupraxia Pharmaceuticals in the 3rd quarter worth approximately $2,077,000. Finally, Royal Bank of Canada grew its stake in Eupraxia Pharmaceuticals by 21.1% in the 1st quarter. Royal Bank of Canada now owns 342,828 shares of the company’s stock valued at $1,125,000 after buying an additional 59,683 shares in the last quarter.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.